Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression

Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression

RNA sequencing of MEK inhibitor (selumetinib)-treated tumors reveals an upregulation of the JAK/STAT3 pathway, with combinatorial therapeutic strategies of JAK/STAT3 inhibitors and selumetinib investigated for the SHH subgroup of medulloblastoma.

Bibliographic Details
Main Authors: Jamie Zagozewski, Stephanie Borlase, Brent J. Guppy, Ludivine Coudière-Morrison, Ghazaleh M. Shahriary, Victor Gordon, Lisa Liang, Stephen Cheng, Christopher J. Porter, Rhonda Kelley, Cynthia Hawkins, Jennifer A. Chan, Yan Liang, Jingjing Gong, Carolina Nör, Olivier Saulnier, Robert J. Wechsler-Reya, Vijay Ramaswamy, Tamra E. Werbowetski-Ogilvie
Format: Article
Language:English
Published: Nature Portfolio 2022-07-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-022-03654-9

Internet

https://doi.org/10.1038/s42003-022-03654-9

Similar Items